Results 151 to 160 of about 62,685 (235)

Urinary Biomarkers and Their Role in the Management of Urothelial Carcinoma: A Narrative Review. [PDF]

J Clin Med
Tichil BP, Besleaga A, Vica Matei ML, Florea A.   +3 more
europepmc   +1 more source

A Novel Technique for the Distal Ureter and Bladder Cuff During Nephroureterectomy: Thulium Laser Resection

Trends in Urology &Men's Health, Volume 17, Issue 5, October 2026.
ABSTRACT The aim of this study was to evaluate the safety and feasibility of a novel technique involving the use of the two‐micron thulium fibre laser (Tm‐laser) to perform bladder cuff excision (BCE) during radical nephroureterectomy (RNU). We conducted a retrospective review of all patients undergoing RNU with BCE for upper tract urothelial carcinoma
Shravankrishna Ananthapadmanabhan, Jeremy Saad, Hong Soh, Darius Ashrafi, Hodo Haxhimolla   +4 more
wiley   +1 more source

Epidermoid Cyst of the Ureter Mimicking Recurrent Urothelial Carcinoma: A Case Report and Brief Literature Review. [PDF]

Am J Case Rep
Halalsheh OM, Hulliel AF, Abualasal A, Aldeqes MI, Obeid A, Sharayah M, Al-Khatib S.   +6 more
europepmc   +1 more source

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

BJU International, Volume 138, Issue 4, Page 607-619, October 2026.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan, Ethan Senior, Jessica Kendall, Jamie B. Oughton, Fiona Collinson, Jon Griffin, Rachel Hubbard, Steven Kennish, Aidan Noon, Derek J. Rosario, Irbaz B. Riaz, Julie Telliez, James W. F. Catto, Syed A. Hussain   +13 more
wiley   +1 more source

Urothelial Carcinoma With Loss of SMARCA4 Expression With the Site of Origin Identified by Detailed Autopsy Investigation. [PDF]

Pathol Int
Kishinami T, Oda Y, Tanei ZI, Osawa T, Manabe R, Watanabe R, Hirosato Y, Uchida Y, Nishibe A, Ujihashi K, Chiba H, Kuwabara T, Ise K, Enda K, Shirai Y, Sugino H, Wang L, Tsuda M, Abe T, Tanaka S.   +19 more
europepmc   +1 more source

Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1‐LaserComplete study)

BJU International, Volume 138, Issue 4, Page 705-713, October 2026.
Objectives To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive ...
Martin J. Connor, Archana Gopalakrishnan, Nikhil Mayor, Eva Bolton, Sami Hamid, Sai Kalpitha Reddy, Tayla Perreau, Eslam Maher, Alexander Light, Samuel Morris, Jiten Jaipura, Mariana Bertoncelli Tanaka, Norma Gibbons, Archie Hughes‐Hallett, Hashim U. Ahmed, Rakesh Heer, Andrew Smith, David Hrouda, Anna Silvanto, Mona El‐Bahrawy, Mathias Winkler   +20 more
wiley   +1 more source

Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. [PDF]

Int J Urol
Kobayashi G, Sekino Y, Miyamoto S, Kobatake K, Kitano H, Goto K, Goriki A, Hieda K, Hayashi T, Sentani K, Hinata N.   +10 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Mixed carcinoma transdifferentiation of bladder urothelial carcinoma after chemotherapy: A case report. [PDF]

Oncol Lett
Zhao L, Huang J, Dong Z, Sun J, Hua R, Wang X, Wang K.   +6 more
europepmc   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, Volume 37, Issue 5, Page 752-760, October 2026.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source